FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200213181> ?p ?o ?g. }

• W4200213181 endingPage "66" @default.
• W4200213181 startingPage "56" @default.
• W4200213181 abstract "The HLA-A*24:02-restricted peptide vaccine targeting Wilms' tumor 1 (WT1) (WT1 vaccine) is a promising therapeutic strategy for ovarian cancer; however, its efficacy varies among patients. In this study, we analyzed WT1-specific immune responses in patients with advanced or recurrent ovarian cancer that was refractory to standard chemotherapies and their associations with clinical outcomes. In 25 patients, the WT1 vaccine was administered subcutaneously weekly for 3 months and biweekly thereafter until disease progression or severe adverse events. We assessed Wilms' tumor 1-specific cytotoxic T lymphocytes (WT1-CTLs) and Wilms' tumor 1 peptide-specific immunoglobulin G (WT1235-IgG). After vaccination, the percentage of tetramer high-avidity population of WT1-CTLs among CD8+ T lymphocytes (%tet-hi WT1-CTL) and the WT1235-IgG titer increased significantly, although the values were extremely low or below the limit of detection before vaccination (%tet-hi WT1-CTL: 0.003%-0.103%.; WT1235-IgG: <0.05-0.077 U/mL). Patients who had %tet-hi WT1-CTL of ≥0.25% (n=6) or WT1235-IgG of ≥0.10 U/mL (n=12) had a significantly longer progression-free survival than those of patients in the other groups. In addition, an increase in WT1235-IgG corresponded to a significantly longer progression-free survival (P=0.0496). In patients with systemic inflammation, as evidenced by elevated C-reactive protein levels, the induction of tet-hi WT1-CTL or WT1235-IgG was insufficient. Decreased serum albumin levels, multiple tumor lesions, poor performance status, and excess ascites negatively influenced the clinical effectiveness of the WT1 vaccine. In conclusion, the WT1 vaccine induced antigen-specific cellular and humoral immunity in patients with refractory ovarian cancer. Both %tet-hi WT1-CTL and WT1235-IgG levels are prognostic markers for the WT1 vaccine." @default.
• W4200213181 created "2021-12-31" @default.
• W4200213181 creator A5000288432 @default.
• W4200213181 creator A5002638004 @default.
• W4200213181 creator A5004685668 @default.
• W4200213181 creator A5004882510 @default.
• W4200213181 creator A5011392452 @default.
• W4200213181 creator A5018100562 @default.
• W4200213181 creator A5021069937 @default.
• W4200213181 creator A5026633755 @default.
• W4200213181 creator A5030032184 @default.
• W4200213181 creator A5038214190 @default.
• W4200213181 creator A5048445299 @default.
• W4200213181 creator A5053854835 @default.
• W4200213181 creator A5055405608 @default.
• W4200213181 creator A5056238856 @default.
• W4200213181 creator A5056664497 @default.
• W4200213181 creator A5058809000 @default.
• W4200213181 creator A5067517267 @default.
• W4200213181 creator A5071117344 @default.
• W4200213181 creator A5081482977 @default.
• W4200213181 creator A5083548459 @default.
• W4200213181 creator A5084112753 @default.
• W4200213181 date "2021-12-08" @default.
• W4200213181 modified "2023-10-01" @default.
• W4200213181 title "Cellular and Humoral Immune Responses Induced by an HLA Class I–restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer" @default.
• W4200213181 cites W1827936231 @default.
• W4200213181 cites W1889335134 @default.
• W4200213181 cites W1968525251 @default.
• W4200213181 cites W1982906652 @default.
• W4200213181 cites W1983398046 @default.
• W4200213181 cites W1985814723 @default.
• W4200213181 cites W1994993231 @default.
• W4200213181 cites W2004772469 @default.
• W4200213181 cites W2009648532 @default.
• W4200213181 cites W2030676407 @default.
• W4200213181 cites W2036635542 @default.
• W4200213181 cites W2045700626 @default.
• W4200213181 cites W2046064533 @default.
• W4200213181 cites W2063690006 @default.
• W4200213181 cites W2082226454 @default.
• W4200213181 cites W2117692326 @default.
• W4200213181 cites W2119896120 @default.
• W4200213181 cites W2120329256 @default.
• W4200213181 cites W2123696077 @default.
• W4200213181 cites W2131681495 @default.
• W4200213181 cites W2134121541 @default.
• W4200213181 cites W2136313650 @default.
• W4200213181 cites W2137074525 @default.
• W4200213181 cites W2145280166 @default.
• W4200213181 cites W2147622445 @default.
• W4200213181 cites W2358063683 @default.
• W4200213181 cites W2589426447 @default.
• W4200213181 cites W2596673995 @default.
• W4200213181 cites W2773771998 @default.
• W4200213181 cites W2785056616 @default.
• W4200213181 cites W2797967795 @default.
• W4200213181 cites W2802266421 @default.
• W4200213181 cites W2884452328 @default.
• W4200213181 cites W2887277666 @default.
• W4200213181 cites W2890261294 @default.
• W4200213181 cites W2893176696 @default.
• W4200213181 cites W2896393991 @default.
• W4200213181 cites W2901054757 @default.
• W4200213181 cites W2911940503 @default.
• W4200213181 cites W2919778409 @default.
• W4200213181 cites W2951714360 @default.
• W4200213181 cites W2993342320 @default.
• W4200213181 doi "https://doi.org/10.1097/cji.0000000000000405" @default.
• W4200213181 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34874330" @default.
• W4200213181 hasPublicationYear "2021" @default.
• W4200213181 type Work @default.
• W4200213181 citedByCount "6" @default.
• W4200213181 countsByYear W42002131812023 @default.
• W4200213181 crossrefType "journal-article" @default.
• W4200213181 hasAuthorship W4200213181A5000288432 @default.
• W4200213181 hasAuthorship W4200213181A5002638004 @default.
• W4200213181 hasAuthorship W4200213181A5004685668 @default.
• W4200213181 hasAuthorship W4200213181A5004882510 @default.
• W4200213181 hasAuthorship W4200213181A5011392452 @default.
• W4200213181 hasAuthorship W4200213181A5018100562 @default.
• W4200213181 hasAuthorship W4200213181A5021069937 @default.
• W4200213181 hasAuthorship W4200213181A5026633755 @default.
• W4200213181 hasAuthorship W4200213181A5030032184 @default.
• W4200213181 hasAuthorship W4200213181A5038214190 @default.
• W4200213181 hasAuthorship W4200213181A5048445299 @default.
• W4200213181 hasAuthorship W4200213181A5053854835 @default.
• W4200213181 hasAuthorship W4200213181A5055405608 @default.
• W4200213181 hasAuthorship W4200213181A5056238856 @default.
• W4200213181 hasAuthorship W4200213181A5056664497 @default.
• W4200213181 hasAuthorship W4200213181A5058809000 @default.
• W4200213181 hasAuthorship W4200213181A5067517267 @default.
• W4200213181 hasAuthorship W4200213181A5071117344 @default.
• W4200213181 hasAuthorship W4200213181A5081482977 @default.
• W4200213181 hasAuthorship W4200213181A5083548459 @default.
• W4200213181 hasAuthorship W4200213181A5084112753 @default.
• W4200213181 hasBestOaLocation W42002131811 @default.
• W4200213181 hasConcept C121608353 @default.

• next